Napredna pretraga

Pregled bibliografske jedinice broj: 549839

In vitro evaluation of a thermally targeted conjugate of a highly potent doxorubicin derivative


Opačak-Bernardi, Teuta; Robinson, Leslie; Abu Ajaj, Khalid; Kratz, Felix; Raucher, Dražen
In vitro evaluation of a thermally targeted conjugate of a highly potent doxorubicin derivative // Proceedings of the 102nd Annual Meeting of the American Association for Cancer Research
Orlando, SAD, 2011. (poster, međunarodna recenzija, sažetak, znanstveni)


Naslov
In vitro evaluation of a thermally targeted conjugate of a highly potent doxorubicin derivative

Autori
Opačak-Bernardi, Teuta ; Robinson, Leslie ; Abu Ajaj, Khalid ; Kratz, Felix ; Raucher, Dražen

Vrsta, podvrsta i kategorija rada
Sažeci sa skupova, sažetak, znanstveni

Izvornik
Proceedings of the 102nd Annual Meeting of the American Association for Cancer Research / - , 2011

Skup
102nd Annual Meeting of the American Association for Cancer Research

Mjesto i datum
Orlando, SAD, 2.-6.4.2011

Vrsta sudjelovanja
Poster

Vrsta recenzije
Međunarodna recenzija

Ključne riječi
Doxorubicin; Targeted drug delivery; Breast cancer

Sažetak
Doxorubicin is an anthracycline used in the treatment of many types of cancer. It intercalates into the strands of DNA to inhibit the progression of topoisomerase II, stopping the cell from replicating. The side effects, however, are severe and include neutropenia, alopecia, nausea, myelosuppression, and cardiotoxicity. Due to its nonspecific effect, high doses are needed to treat cancer cells. These high doses are inadvertently harmful to normal cells. n-Butyldiacatodoxorubicin (NBD) is a doxorubicin derivative that is converted in vivo to 2-pyrrolinodoxorubicin that is ~ 1000-fold more active than doxorubicin. Because of its high potency, an efficient drug delivery system is needed in order to deliver NBD to the tumor site. To retain potent antitumor activity while reducing systemic toxicity, NBD was coupled to a thermally responsive macromolecular carrier. The macromolecular carrier is based on elastin-like polypeptide (ELP) which remains in solution at physiological temperature and accumulates in the tumor site when external hyperthermia is applied. The N-terminus of ELP was modified with the cell penetrating peptide (CPP) SynB1. SynB1 is a 19 amino acid peptide derived from porcine leukocytes which facilitates cellular uptake of the ELP carrier. NBD was attached to a terminal cysteine residue of ELP by conjugation of a 6-maleimidocaproyl hydrazone derivative of NBD. This NBD drug bears an acid-sensitive linker that is cleavable at the lysosomal/endosomal pH, which allows a controlled intracellular release of the drug. The ELP-delivered NBD inhibited MCF-7 cells growth in the nanomolar range. In addition, inhibition of cell proliferation was enhanced two-fold when hyperthermia was applied and cell proliferation was accompanied by apoptosis, which was enhanced 3-fold in MCF-7 cells when SynB1-ELP-NBD aggregation was induced with hyperthermia. These results suggest that the SynB1-ELP-NBD conjugate is a promising candidate for investigating its thermally targeting properties against solid tumors in animal models.

Izvorni jezik
Engleski

Znanstvena područja
Biologija, Temeljne medicinske znanosti



POVEZANOST RADA


Projekt / tema
219-0000000-3364 - Ciljano toplinsko dopremanje lijekova u solidne tumore (Dražen Raucher, )
219-2192190-2069 - Fizikalno-kemijski i metabolički čimbenici rizika stvaranja kamenaca (Aleksandar Včev, )

Ustanove
Medicinski fakultet, Osijek

Časopis indeksira:


  • MEDLINE